Studying eczema cream safety during pregnancy
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study compares the health of mothers and their babies in two groups: women with eczema who used ruxolitinib cream during pregnancy and those who did not. It aims to see if the cream is safe for both mother and child.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 15 and 50 years old.
- You have been diagnosed with mild to moderate atopic dermatitis (eczema).
- You are either pregnant now or had a pregnancy outcome (like giving birth) within the last 12 months.
- You either used the study cream (ruxolitinib) during pregnancy or did not use any ruxolitinib cream during pregnancy.
- You are willing to give permission for the study team to contact you, your baby's doctor, and your own doctor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at women who used a topical eczema cream called ruxolitinib (Opzelura) or steroid creams during pregnancy. The goal is to compare pregnancy outcomes and baby health up to one year after birth.
This trial tests a cream called Opzelura (ruxolitinib) for people with mild-to-moderate eczema on at least two body areas. It aims to see how well the cream works in everyday use for people ages 2 and older.
This study tracks pregnancy and baby outcomes in people who have been pregnant while taking tralokinumab, a medication for eczema. It compares those outcomes to other eczema treatment groups to help doctors understand potential risks or reassuring effects.
This study tracks the safety of abrocitinib (CIBINQO) during pregnancy and what it may mean for the baby. You may join if you were pregnant recently or are currently pregnant and have taken CIBINQO, or if you have moderate-to-severe atopic dermatitis.
This study tests a new moisturizing product (RV4421B) for people with mild to moderate atopic dermatitis (eczema). Participants will use the product along with their usual steroid cream for 12 weeks to see how well it works and if it’s safe for different ages, from babies to adults.
This trial tests if an ointment called QLM3003 is safe and helps adults with mild to moderate atopic dermatitis (eczema). It may be a new treatment option for people whose eczema affects small areas of skin.
Hear when a new Pregnancy Related trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.